Alpha-Mannosidosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Alpha-Mannosidosis Market Outlook
Thelansis’s “Alpha-Mannosidosis Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Alpha-Mannosidosis treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Alpha-Mannosidosis
Overview
Alpha-mannosidosis
is an autosomal recessive lysosomal storage disease caused by MAN2B1 gene
mutations. It is diagnosed by detecting low levels of acidic alpha-mannosidase
enzyme activity in peripheral blood leukocytes or cultured skin fibroblasts,
with affected individuals displaying 5–15% of regular leukocyte activity. In
most patients, the disease is clinically recognised in the first decade of
life, progression is slow, and ataxia develops between 20 to 30 years.
Long-term enzyme replacement therapy (ERT) is a treatment option for
alpha-mannosidosis, and the first human recombinant form of alpha-mannosidase
available for ERT is velmanase alfa. Patients with alpha-mannosidosis who were
treated with velmanase alfa improved in biomarkers, motor function, pulmonary
function, immunologic profile, and quality of life in clinical trials.
Intracellular accumulation of mannose-rich oligosaccharides causes various
clinical symptoms, including hearing loss, intellectual disabilities, and motor
function and speech impairment.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment